RxDoctor Payments Data

Amed Napoles Garcia, APRN

Psychiatric/Mental Health · Hollywood, FLNPI 1821700063

Payments from drug & device makers

$3,972in general payments, 2019–2025

Across 178 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$571
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$438
  • Axsome Therapeutics, Inc.$377
  • Otsuka America Pharmaceutical, Inc.$338
  • Teva Pharmaceuticals USA, Inc.$336
  • AbbVie$305
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,972 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$11,072
Medicare patients
24
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$17,291
Duloxetine Hcl138$2,361
Mirtazapine110$1,263
Buspirone Hcl153$1,163
Memantine Hcl134$1,114
Escitalopram Oxalate267$1,053
Quetiapine Fumarate100$1,003
Sertraline Hcl141$972
Clonazepam141$935
Trazodone Hcl230$876
Aripiprazole15$827
Temazepam112$617
Bupropion XlBupropion Hcl62$587
Venlafaxine Hcl ErVenlafaxine Hcl54$439
Donepezil Hcl61$378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$338$17,29112 claims
Almatica Pharma LLCSertraline Hcl$121$972141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →